论文部分内容阅读
目的：探讨淋巴浆细胞样淋巴瘤的预后，以及治疗对该病预后的影响。方法：对４１例淋巴浆细胞样淋巴瘤患者均进行了较积极的治疗及长期随访，并经统计学处理。结果：全组中位生存期３９．４个月。导致生存期缩短的主要原因是就诊时临床分期已达Ⅲ、Ⅳ期（Ｐ＜０．０１）；具有Ｂ症状（Ｐ＜０．０５）；骨髓及结外受累（Ｐ＜０．０１）。综合治疗的无瘤生存期及１年生存率高于单纯化疗（Ｐ＜０．０５），但二者生存期无显著差别（Ｐ＞０．０５）。结论：对淋巴浆细胞样淋巴瘤不应过于积极治疗，应静观其变化，适时给予必要的干预，治疗主要目的应是改善患者的生存质量。
Objective: To explore the prognosis of lymphoplasmacytic lymphoma and its effect on the prognosis of this disease. Methods: Forty-one patients with lymphoplasmacytic lymphoma were treated with active treatment and long-term follow-up. Statistical analysis was performed. Results: The median survival time of the whole group was 39.4 months. The main reasons for the shortened survival time were clinical stage III and IV (P<0.01); B symptoms (P<0.05); bone marrow and extranodal involvement (P<0.01). The disease-free survival and 1-year survival rate of comprehensive treatment were higher than that of chemotherapy alone (P<0.05), but there was no significant difference between the two groups (P>0.05). Conclusions: Lymphocytic-like lymphoma should not be treated too aggressively. Observe its changes and give necessary interventions at the right time. The main purpose of treatment should be to improve the patient’s quality of life.